12 个亚太国家（2011 年）的区域耐药监测计划结果。
Regional resistance surveillance program results for 12 Asia-Pacific nations (2011).
机构信息
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2013 Nov;57(11):5721-6. doi: 10.1128/AAC.01121-13. Epub 2013 Aug 19.
Abstract
The Regional Resistance Surveillance program monitored susceptibility rates and developing resistance by geographic region, including 12 Asia-Pacific (APAC) countries. Reference broth microdilution methods for susceptibility/interpretations were applied, processing 5,053 strains. Among Staphylococcus aureus isolates (37% methicillin-resistant S. aureus [MRSA], highest in South Korea [73%]), linezolid (LZD), tigecycline (TIG), and vancomycin were 100% active, but 33 and 34% of strains were levofloxacin (LEV) or macrolide resistant, respectively. Streptococcus pneumoniae was most resistant to β-lactams and macrolides (45%) but was LZD, LEV, and TIG susceptible (>98%). Extended-spectrum β-lactamase (ESBL) phenotype rates in Escherichia coli and Klebsiella spp. were 48 and 47%, respectively, and were highest in Taiwan, at 75 to 91%. The best anti-ESBL-phenotype agents were amikacin (81 to 96% susceptible), colistin (COL; >98%), TIG (>98%), and carbapenems (81 to 97%). Pseudomonas aeruginosa showed ≥20% resistance to all drugs except COL (99% susceptible). In conclusion, endemic evolving antimicrobial resistances in APAC nations show compromised roles for many commonly used antimicrobials.
摘要
区域性耐药监测计划监测了地理区域的耐药率和耐药发展情况，包括亚太地区 12 个国家。应用了参考肉汤微量稀释法进行药敏/解释，共处理了 5053 株菌株。在金黄色葡萄球菌分离株中（37%耐甲氧西林金黄色葡萄球菌[MRSA]，韩国最高[73%]），利奈唑胺（LZD）、替加环素（TIG）和万古霉素的活性均为 100%，但分别有 33%和 34%的菌株对左氧氟沙星（LEV）或大环内酯类耐药。肺炎链球菌对β-内酰胺类和大环内酯类（45%）最耐药，但对 LZD、LEV 和 TIG 敏感（>98%）。大肠埃希菌和克雷伯菌属的产超广谱β-内酰胺酶（ESBL）表型率分别为 48%和 47%，在台湾最高，为 75%至 91%。针对 ESBL 表型的最佳抗生素为阿米卡星（81%至 96%敏感）、黏菌素（COL；>98%）、TIG（>98%）和碳青霉烯类（81%至 97%）。除 COL（99%敏感）外，铜绿假单胞菌对所有药物的耐药率均≥20%。总之，亚太国家的流行的抗菌药物耐药性正在不断演变，许多常用抗菌药物的作用受到影响。
相似文献
1
Regional resistance surveillance program results for 12 Asia-Pacific nations (2011).12 个亚太国家（2011 年）的区域耐药监测计划结果。
Antimicrob Agents Chemother. 2013 Nov;57(11):5721-6. doi: 10.1128/AAC.01121-13. Epub 2013 Aug 19.
2
The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.替加环素评估和监测试验；评估替加环素和其他选定抗生素对 2004 年至 2016 年期间从法国收集的革兰氏阳性和革兰氏阴性病原体的活性。
Antimicrob Resist Infect Control. 2018 May 30;7:68. doi: 10.1186/s13756-018-0360-y. eCollection 2018.
3
In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.替加环素和对照药物（2014-2016 年）对世界卫生组织“重点病原体”的体外活性及 2004-2016 年抗菌药物耐药性的纵向评估：来自 T.E.S.T.研究的报告。
Int J Antimicrob Agents. 2018 Oct;52(4):474-484. doi: 10.1016/j.ijantimicag.2018.07.003. Epub 2018 Aug 21.
4
Antimicrobial susceptibility among Gram-positive and Gram-negative organisms collected from the Latin American region between 2004 and 2015 as part of the Tigecycline Evaluation and Surveillance Trial.作为替加环素评估与监测试验的一部分，2004年至2015年间从拉丁美洲地区收集的革兰氏阳性和革兰氏阴性生物体的抗菌药敏性。
Ann Clin Microbiol Antimicrob. 2017 Jul 12;16(1):50. doi: 10.1186/s12941-017-0222-0.
5
Resistance surveillance program report for selected European nations (2011).选定欧洲国家（2011 年）耐药监测计划报告。
Diagn Microbiol Infect Dis. 2014 Apr;78(4):429-36. doi: 10.1016/j.diagmicrobio.2013.10.008. Epub 2013 Oct 14.
6
Antimicrobial susceptibility among gram-positive and gram-negative blood-borne pathogens collected between 2012-2016 as part of the Tigecycline Evaluation and Surveillance Trial.2012-2016 年间收集的革兰氏阳性和革兰氏阴性血源性病原体的抗菌药敏性，作为替加环素评估和监测试验的一部分。
Antimicrob Resist Infect Control. 2018 Dec 13;7:152. doi: 10.1186/s13756-018-0441-y. eCollection 2018.
7
In vitro activity of ceftazidime-avibactam and comparators against Gram-negative bacterial isolates collected in the Asia-Pacific region as part of the INFORM program (2015-2017).亚太地区 INFORM 项目（2015-2017 年）收集的革兰氏阴性细菌分离株的头孢他啶-阿维巴坦和对照药物的体外活性。
Ann Clin Microbiol Antimicrob. 2020 Apr 1;19(1):14. doi: 10.1186/s12941-020-00355-1.
8
Antimicrobial susceptibility trends among gram-positive and -negative clinical isolates collected between 2005 and 2012 in Mexico: results from the Tigecycline Evaluation and Surveillance Trial.2005年至2012年期间在墨西哥收集的革兰氏阳性和阴性临床分离株的抗菌药敏趋势：替加环素评估与监测试验的结果
Ann Clin Microbiol Antimicrob. 2015 Dec 15;14:53. doi: 10.1186/s12941-015-0116-y.
9
In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018).临床呼吸道分离株对头孢他啶-阿维巴坦及对照药物的体外抗菌敏感性（2016 - 2018年）
BMC Infect Dis. 2021 Jun 23;21(1):600. doi: 10.1186/s12879-021-06153-0.
10
Antimicrobial susceptibility of Gram-negative and Gram-positive bacteria collected from Eastern Europe: Results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2011-2016.革兰氏阴性菌和革兰氏阳性菌对来自东欧的抗生素敏感性：替加环素评估和监测试验（T.E.S.T.），2011-2016 年的结果。
J Glob Antimicrob Resist. 2019 Jun;17:44-52. doi: 10.1016/j.jgar.2018.11.007. Epub 2018 Nov 13.
引用本文的文献
1
Molecular Characterization of Clinical Isolates of Methicillin-Resistant from Chonburi, Thailand.泰国春武里耐甲氧西林临床分离株的分子特征分析
Pathogens. 2025 Apr 24;14(5):406. doi: 10.3390/pathogens14050406.
2
Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.临床分离株中黏菌素耐药性的流行情况：一项系统评价和荟萃分析。
Front Microbiol. 2024 Oct 9;15:1477836. doi: 10.3389/fmicb.2024.1477836. eCollection 2024.
3
High prevalence of ESBL-producing E. coli phylogroup B2 clinical isolates in northeastern Thailand.泰国东北部产 ESBL 大肠埃希菌 B2 组临床分离株的高流行率。
BMC Microbiol. 2024 Oct 22;24(1):425. doi: 10.1186/s12866-024-03582-0.
4
Comparing the Phylogenetic Distribution of Multilocus Sequence Typing, Staphylococcal Protein A, and Staphylococcal Cassette Chromosome Mec Types in Methicillin-Resistant Staphylococcus Aureus (MRSA) in Korea from 1994 to 2020.比较1994年至2020年韩国耐甲氧西林金黄色葡萄球菌（MRSA）中多位点序列分型、葡萄球菌蛋白A和葡萄球菌盒式染色体mec型的系统发育分布。
Antibiotics (Basel). 2023 Sep 1;12(9):1397. doi: 10.3390/antibiotics12091397.
5
Methicillin-resistant isolates derived from humans and animals in Yogyakarta, Indonesia.来自印度尼西亚日惹人类和动物的耐甲氧西林分离株。
Vet World. 2023 Jan;16(1):239-245. doi: 10.14202/vetworld.2023.239-245. Epub 2023 Jan 31.
6
Epidemiology of extended-spectrum β-lactamases in in Taiwan for over two decades.台湾地区超广谱β-内酰胺酶二十多年的流行病学情况。
Front Microbiol. 2023 Jan 25;13:1060050. doi: 10.3389/fmicb.2022.1060050. eCollection 2022.
7
Inhibitory Effects of Selected Medicinal Plants on Bacterial Growth of Methicillin-Resistant .某些药用植物对耐甲氧西林金黄色葡萄球菌生长的抑制作用
Molecules. 2022 Nov 11;27(22):7780. doi: 10.3390/molecules27227780.
8
Molecular characterization of multidrug-resistant ESKAPEE pathogens from clinical samples in Chonburi, Thailand (2017-2018).泰国春武里府临床样本中 ESKAPEE 多重耐药病原体的分子特征（2017-2018 年）。
BMC Infect Dis. 2022 Aug 17;22(1):695. doi: 10.1186/s12879-022-07678-8.
9
Rhamnolipid-Coated Iron Oxide Nanoparticles as a Novel Multitarget Candidate against Major Foodborne E. coli Serotypes and Methicillin-Resistant S. aureus.杆菌脂-氧化铁纳米颗粒作为一种新型的多靶点候选物，可对抗主要食源性病原体大肠杆菌血清型和耐甲氧西林金黄色葡萄球菌。
Microbiol Spectr. 2022 Aug 31;10(4):e0025022. doi: 10.1128/spectrum.00250-22. Epub 2022 Jul 19.
10
Discrimination of Methicillin-resistant by MALDI-TOF Mass Spectrometry with Machine Learning Techniques in Patients with Bacteremia.采用机器学习技术的基质辅助激光解吸电离飞行时间质谱法对菌血症患者耐甲氧西林情况的鉴别
Pathogens. 2022 May 16;11(5):586. doi: 10.3390/pathogens11050586.
本文引用的文献
1
Update of contemporary antimicrobial resistance rates across China: reference testing results for 12 medical centers (2011).当代中国抗菌药物耐药率更新：12 家医疗中心的参考检测结果（2011 年）。
Diagn Microbiol Infect Dis. 2013 Nov;77(3):258-66. doi: 10.1016/j.diagmicrobio.2013.07.003. Epub 2013 Sep 18.
2
An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011.利奈唑胺的国际活动和谱分析：ZAAPS 计划 2011 年的结果。
Diagn Microbiol Infect Dis. 2013 Jun;76(2):206-13. doi: 10.1016/j.diagmicrobio.2013.01.025. Epub 2013 Mar 9.
3
Trending 7 years of in vitro activity of tigecycline and comparators against Gram-positive and Gram-negative pathogens from the Asia-Pacific region: Tigecycline Evaluation Surveillance Trial (TEST) 2004-2010.亚太地区革兰阳性和革兰阴性病原菌的替加环素及对照药物 7 年体外活性趋势：替加环素评估监测研究（TEST）2004-2010。
Int J Antimicrob Agents. 2012 Jun;39(6):490-5. doi: 10.1016/j.ijantimicag.2012.02.018. Epub 2012 Apr 23.
4
Mechanisms of resistance and clinical relevance of resistance to β-lactams, glycopeptides, and fluoroquinolones.β-内酰胺类、糖肽类和氟喹诺酮类耐药的机制及其临床相关性。
Mayo Clin Proc. 2012 Feb;87(2):198-208. doi: 10.1016/j.mayocp.2011.12.003.
5
Carbapenems: past, present, and future.碳青霉烯类抗生素：过去、现在和未来。
Antimicrob Agents Chemother. 2011 Nov;55(11):4943-60. doi: 10.1128/AAC.00296-11. Epub 2011 Aug 22.
6
Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus.抗革兰阳性菌药物对耐甲氧西林金黄色葡萄球菌的临床活性。
J Antimicrob Chemother. 2011 May;66 Suppl 4:iv17-iv21. doi: 10.1093/jac/dkr073.
7
Trends in carbapenemase-producing Escherichia coli and Klebsiella spp. from Europe and the Americas: report from the SENTRY antimicrobial surveillance programme (2007-09).来自欧洲和美洲的产碳青霉烯酶大肠杆菌和克雷伯菌属的趋势：哨兵抗菌监测项目（2007 - 2009年）报告
J Antimicrob Chemother. 2011 Jun;66(6):1409-11. doi: 10.1093/jac/dkr081. Epub 2011 Mar 18.
8
New Delhi metallo-beta-lactamase (NDM-1): towards a new pandemia?新德里金属β-内酰胺酶（NDM-1）：会引发一场新的大流行吗？
Clin Microbiol Infect. 2010 Dec;16(12):1699-701. doi: 10.1111/j.1469-0691.2010.03385.x.
9
Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study.印度、巴基斯坦和英国出现新的抗生素耐药机制：一项分子、生物学和流行病学研究。
Lancet Infect Dis. 2010 Sep;10(9):597-602. doi: 10.1016/S1473-3099(10)70143-2. Epub 2010 Aug 10.
10
The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008).对 2008 年在亚洲-西太平洋地区 8 个国家分离的病原菌进行的替加环素体外评估。
J Infect. 2010 Jun;60(6):440-51. doi: 10.1016/j.jinf.2010.03.024. Epub 2010 Mar 31.
Zotero 插件